Vitreous Fatty Amides and Acyl Carnitines Are Altered in Intermediate Age-Related Macular Degeneration

Purpose Age-related macular degeneration (AMD) is the leading cause of visual impairment worldwide. In this study, we aimed to investigate the vitreous humor metabolite profiles of patients with intermediate AMD using untargeted metabolomics. Methods We performed metabolomics using high-resolution liquid chromatography mass spectrometry on the vitreous humor of 31 patients with intermediate AMD and 30 controls who underwent vitrectomy for epiretinal membrane with or without cataract surgery. Univariate analyses after false discovery rate correction were performed to discriminate the metabolites and identify the significant metabolites of intermediate AMD. For biologic interpretation, enrichment and pathway analysis were conducted using MetaboAnalyst 5.0. Results Of the 858 metabolites analyzed in the vitreous humor, 258 metabolites that distinguished patients with AMD from controls were identified (P values < 0.05). Ascorbic acid and uric acid levels increased in the AMD group (all P values < 0.05). The acyl carnitines, such as acetyl L-carnitine (1.37-fold), and fatty amides, such as anandamide (0.9-fold) and docosanamide (0.67-fold), were higher in patients with intermediate AMD. In contrast, nicotinamide (−0.55-fold), and succinic acid (−1.69-fold) were lower in patients with intermediate AMD. The metabolic pathway related oxidation of branched chain fatty acids and carnitine synthesis showed enrichment. Conclusions Multiple metabolites related to fatty amides and acyl carnitine were found to be increased in the vitreous humor of patients with intermediate AMD, whereas succinic acid and nicotinamide were reduced, suggesting that altered metabolites related to fatty amides and acyl carnitines and energy metabolism may be implicated in the etiology of AMD.

[1]  Joan W. Miller,et al.  Dyslipidemia in age-related macular degeneration , 2022, Eye.

[2]  Dean P. Jones,et al.  Plasma Metabolomics of Intermediate and Neovascular Age-Related Macular Degeneration Patients , 2021, Cells.

[3]  Haixin Wang,et al.  Untargeted metabolomics for uncovering plasma biological markers of wet age-related macular degeneration , 2021, Aging.

[4]  Minoru Kanehisa,et al.  KEGG: integrating viruses and cellular organisms , 2020, Nucleic Acids Res..

[5]  J. Seo,et al.  Comparison of risk allele frequencies of single nucleotide polymorphisms associated with age-related macular degeneration in different ethnic groups , 2020, BMC Ophthalmology.

[6]  C. Pan,et al.  Metabolomics in Age-Related Macular Degeneration: A Systematic Review , 2020, Investigative ophthalmology & visual science.

[7]  S. MacGregor,et al.  The effects of eight serum lipid biomarkers on age-related macular degeneration risk: a Mendelian randomization study. , 2020, International journal of epidemiology.

[8]  H. Hense,et al.  Integrating metabolomics, genomics and disease pathways in age-related macular degeneration: The EYE-RISK Consortium. , 2020, Ophthalmology.

[9]  Meiqin He,et al.  Metabolomic Profiling of the Aqueous Humor in Patients with Wet Age-Related Macular Degeneration using UHPLC-MS/MS. , 2020, Journal of proteome research.

[10]  Gui-Shuang Ying,et al.  Age-Related Macular Degeneration Preferred Practice Pattern®. , 2019, Ophthalmology.

[11]  Inês Laíns,et al.  Human Plasma Metabolomics in Age-Related Macular Degeneration: Meta-Analysis of Two Cohorts , 2019, Metabolites.

[12]  A. D. den Hollander,et al.  Metabolomics in serum of patients with non-advanced age-related macular degeneration reveals aberrations in the glutamine pathway , 2019, PloS one.

[13]  Jaeseung Kang,et al.  Association of vitreous vitamin C depletion with diabetic macular ischemia in proliferative diabetic retinopathy , 2019, PloS one.

[14]  A. D. den Hollander,et al.  Metabolomics and Age-Related Macular Degeneration , 2018, Metabolites.

[15]  Dean P. Jones,et al.  The Carnitine Shuttle Pathway is Altered in Patients With Neovascular Age-Related Macular Degeneration , 2018, Investigative ophthalmology & visual science.

[16]  P. Mitchell,et al.  Age-related macular degeneration , 2018, The Lancet.

[17]  Imre Lengyel,et al.  A new perspective on lipid research in age-related macular degeneration , 2018, Progress in Retinal and Eye Research.

[18]  Ivana K. Kim,et al.  Human Plasma Metabolomics Study across All Stages of Age-Related Macular Degeneration Identifies Potential Lipid Biomarkers. , 2017, Ophthalmology.

[19]  M. Maccarrone,et al.  Neuroprotection by (Endo)Cannabinoids in Glaucoma and Retinal Neurodegenerative Diseases , 2017, Current neuropharmacology.

[20]  C. Klaver,et al.  Systemic and ocular fluid compounds as potential biomarkers in age-related macular degeneration. , 2018, Survey of ophthalmology.

[21]  Michael W. Country,et al.  Retinal metabolism: A comparative look at energetics in the retina , 2017, Brain Research.

[22]  Jost B. Jonas,et al.  Updates on the Epidemiology of Age‐Related Macular Degeneration , 2017, Asia-Pacific journal of ophthalmology.

[23]  W. Willett,et al.  Dietary intake of α-linolenic acid and risk of age-related macular degeneration. , 2017, The American journal of clinical nutrition.

[24]  Ivana K. Kim,et al.  Human plasma metabolomics in age-related macular degeneration (AMD) using nuclear magnetic resonance spectroscopy , 2017, PloS one.

[25]  E. Segal,et al.  Involvement of a gut–retina axis in protection against dietary glycemia-induced age-related macular degeneration , 2017, Proceedings of the National Academy of Sciences.

[26]  Timothy A. Blenkinsop,et al.  Nicotinamide Ameliorates Disease Phenotypes in a Human iPSC Model of Age-Related Macular Degeneration. , 2017, Cell stem cell.

[27]  Hyungwon Choi,et al.  Customized Consensus Spectral Library Building for Untargeted Quantitative Metabolomics Analysis with Data Independent Acquisition Mass Spectrometry and MetaboDIA Workflow. , 2017, Analytical chemistry.

[28]  Youngsoo Kim,et al.  Carboxymethyl-lysine-modified plasma proteins in age-related macular degeneration , 2017, Biotechnology and Bioprocess Engineering.

[29]  D. Kazan,et al.  Metabolic Biomarkers and Neurodegeneration: A Pathway Enrichment Analysis of Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis. , 2016 .

[30]  A. Giersch,et al.  The Endocannabinoid System in the Retina: From Physiology to Practical and Therapeutic Applications , 2016, Neural plasticity.

[31]  Yue Han,et al.  CETP/LPL/LIPC gene polymorphisms and susceptibility to age-related macular degeneration , 2015, Scientific Reports.

[32]  Zhifeng Wu,et al.  Metabolomic Analysis of Human Vitreous in Rhegmatogenous Retinal Detachment Associated With Choroidal Detachment. , 2015, Investigative ophthalmology & visual science.

[33]  K. Palczewski,et al.  Serum levels of lipid metabolites in age‐related macular degeneration , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  G. Abecasis,et al.  Age-related macular degeneration: genetics and biology coming together. , 2014, Annual review of genomics and human genetics.

[35]  P. Jiang,et al.  Investigating the pathological processes of rhegmatogenous retinal detachment and proliferative vitreoretinopathy with metabolomics analysis. , 2014, Molecular bioSystems.

[36]  R. Klein,et al.  Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. , 2014, The Lancet. Global health.

[37]  Sina Farsiu,et al.  Progression of intermediate age-related macular degeneration with proliferation and inner retinal migration of hyperreflective foci. , 2013, Ophthalmology.

[38]  Usha Chakravarthy,et al.  Clinical classification of age-related macular degeneration. , 2013, Ophthalmology.

[39]  Joan W. Miller,et al.  Age-related macular degeneration revisited--piecing the puzzle: the LXIX Edward Jackson memorial lecture. , 2013, American journal of ophthalmology.

[40]  B. McManus,et al.  The Human Serum Metabolome , 2011, PloS one.

[41]  Margaret A. Pericak-Vance,et al.  Genetic variants near TIMP3 and high-density lipoprotein–associated loci influence susceptibility to age-related macular degeneration , 2010, Proceedings of the National Academy of Sciences.

[42]  David S. Wishart,et al.  SMPDB: The Small Molecule Pathway Database , 2009, Nucleic Acids Res..

[43]  Philip Hunter,et al.  Reading the metabolic fine print , 2009, EMBO reports.

[44]  S. Black,et al.  CARNITINE HOMEOSTASIS, MITOCHONDRIAL FUNCTION, AND CARDIOVASCULAR DISEASE. , 2009, Drug discovery today. Disease mechanisms.

[45]  Usha Chakravarthy,et al.  The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. , 2008, Ophthalmology.

[46]  デュワン,アンドリュー,et al.  Diagnosis and treatment of age-related macular degeneration , 2007 .

[47]  I. Matias,et al.  Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. , 2006, Prostaglandins, leukotrienes, and essential fatty acids.

[48]  A. Ramé [Age-related macular degeneration]. , 2006, Revue de l'infirmiere.

[49]  P. Bénit,et al.  Succinate dehydrogenase deficiency in human , 2005, Cellular and Molecular Life Sciences CMLS.

[50]  George A. Williams,et al.  The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1. , 1999, Controlled clinical trials.

[51]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[52]  Stem Cell Investigation , 2022 .

[53]  S. Roth,et al.  Clinical Interventions in Aging , 2022 .